Nurse Practitioner Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Jacinta Tran

Nurse Practitioner, Family La Jolla, CA Nurse Practitioner

NPI 1225487069 CMS profile 10547532

9898 Genesee Ave, La Jolla, CA 92037

Open in the dashboard

General payments

$16,394

238 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Jacinta Tran of La Jolla, CA is reported in the CMS Open Payments database as having received $16,394 across 238 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 99th percentile of Nurse Practitioner, Family profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $8,046 104
2024 General $3,014 56
2023 General $3,649 46
2022 General $656 18
2021 General $1,030 14

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Jacinta Tran
  • Nurse Practitioner, Family median
  • Middle half of Nurse Practitioner, Family
  • National median

In program year 2025, general payments to Jacinta Tran were reported at $8,046. Among 107,232 Nurse Practitioner, Family profiles paid that year, the median was $168 and the middle half received between $53 and $521.

Show as a table
Year Jacinta Tran Nurse Practitioner, Family median Middle half National median
2019 $0 $39 $18–$91 $163
2020 $0 $32 $17–$76 $114
2021 $1,030 $124 $35–$379 $132
2022 $656 $141 $44–$430 $149
2023 $3,649 $154 $49–$476 $160
2024 $3,014 $165 $51–$504 $164
2025 $8,046 $168 $53–$521 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. Medtronic, Inc. $10,503 135 payments
  2. Boston Scientific Corporation $1,997 32 payments
  3. Abbott Laboratories $1,895 37 payments
  4. Impulse Dynamics (USA) Inc. $667 8 payments
  5. AstraZeneca Pharmaceuticals LP $363 3 payments
  6. Kestra Medical Technology Services, Inc. $182 1 payment
  7. Novartis Pharmaceuticals Corporation $146 3 payments
  8. Abiomed $137 1 payment
  9. Inspire Medical Systems, Inc. $102 1 payment
  10. iRhythm Technologies, Inc. $71 3 payments
  11. Other $332 14 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $8,704 182 payments
  2. Travel and Lodging $6,836 40 payments
  3. Consulting Fee $560 3 payments
  4. Education $294 13 payments
Products named General payments · program years 2021–2025
  1. LINQ II $2,604 47 payments
  2. OPTIMIZER Cardiovascular Device $667 8 payments
  3. OPTIMIZER Cardiovascular Device $667 8 payments
  4. Confirm Rx $491 4 payments
  5. LUX-Dx Insertable Cardiac Monitor $487 10 payments
  6. AVEIR $344 7 payments
  7. Micra $228 4 payments
  8. AZURE XT DR MRI SURESCAN $209 10 payments
  9. Assure WCD $182 1 payment
  10. MITRACLIP $164 1 payment
  11. Other $2,890 81 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Billing to Medicare

Part B · data year 2024 · 14 billing codes

Paid by Medicare

$195,185

Medicare's payments for the services billed

Medicare patients

1,795

Average age 80

Services billed

5,004

751 women, 1,044 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Atrial fibrillation 64%
Ischemic heart disease 50%
Arthritis 47%
Heart failure 46%
Chronic kidney disease 34%
Diabetes 27%
Depression 20%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

4 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
Arcalyst
  • Kiniksa Pharmaceuticals International, plc $39
$39 — —
FUROSCIX
  • SCPHARMACEUTICALS INC. $26
$26 — —
OPSUMIT
  • Actelion Pharmaceuticals US, Inc. $8
$8 — —
UPTRAVI
  • Actelion Pharmaceuticals US, Inc. $8
$8 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

Records

238 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Nurse Practitioner, Family in California

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record